Sangamo prices its secondary offering

Sangamo BioSciences (SGMO) prices its offering of 4,444,444 common shares at $22.50. The overallotment is 666,666 shares.

The company expects it to close on or about March 26.

Proceeds to fund general corporate purposes including R&D, expanding manufacturing capabilities, clinical trials and potential acquisitions.

From other sites
Comments (1)
  • MineMan
    , contributor
    Comments (583) | Send Message
    It is clear to me that things at Sangamo are heating up. There is no longer a need for the frugality of the past. Expect to see multiple shots on goal in the near future, which IMO, will include a 50/50 chance of another suitable acquisition or merger.
    With the advances in the technologies surrounding Sangamo IP, like sequencing, things are advancing int the "Engineering Genetic Cures" area quite rapidly.
    Judging from the thousands or articles published about zinc Fingers, the fondatio of SGMO IP, the possibilities are near limitless.
    Certainly a company, certainly a company clearly involved in the coming Paradigm shift in how we treat diseases in thenot so distant future.
    21 Mar 2014, 09:06 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs